Frequency-dependent effect of intravenous administration of human adipose-derived mesenchymal stem cell therapy for severe Systemic Lupus Erythematosus: A case report

间充质干细胞 医学 脂肪组织 全身给药 系统性狼疮 干细胞疗法 干细胞 系统性红斑狼疮 遗产管理(遗嘱认证法) 药理学 内科学 病理 疾病 生物 生物技术 遗传学 法学 体内 政治学
作者
Ridhima Vij,Mallika Tripathy,Hosu Kim,Hyeonggeun Park,Thanh Cheng,Djamchid Lotfi,Donna Chang
出处
期刊:Journal of translational autoimmunity [Elsevier BV]
卷期号:5: 100166-100166 被引量:3
标识
DOI:10.1016/j.jtauto.2022.100166
摘要

Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease that involves abnormal activation of immune response, affecting multiple organs, including joints, kidneys, lungs, skin, and the hematopoietic system, thereby impairing their normal function. Despite there being no cure for SLE, Mesenchymal Stem Cell (MSC) therapy offers hope for SLE patients because of its potent role in immunomodulation. Here, we report a case of a 65-year-old female battling with SLE for almost 30 years and on a treatment regimen consisting of several medications. Given the level of immunosuppression associated with conventional SLE treatments, the subject was initially enrolled as a participant in a study protocol designed to provide immune protection against COVID-19. The subject received multiple infusions of autologous Hope Biosciences adipose-derived MSCs (HB-adMSCs) which significantly improved her SLE symptoms and functionality that led the patient's physician to discontinue her Rituximab regime. Based on her response to HB-adMSC therapy, the subject was approved to receive a set of nine infusion treatments to specifically treat her SLE symptoms. Over the course of ∼ one year, the first six infusions were given on a monthly basis, while the remaining three were administered bimonthly - each with a dose of 200 million HB-adMSCs. Since the beginning of the treatment, the subject showed remarkable improvements in her SLE symptoms, as demonstrated by changes in her SF-36 questionnaire responses, Visual Analog Scale (VAS) scores, and C-Reactive Protein (CRP) measurements; however, worsening of the symptoms was noted later during treatment course (when the frequency of infusions changed to bimonthly). Although the shift in remission-relapse cycle is not fully understood, however, the data suggest that treatment frequency might be the key player. No serious adverse events occurred during the entire treatment period. Further research is needed to evaluate the results of this study.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Jasper应助覃昔丰采纳,获得10
1秒前
wangli发布了新的文献求助10
2秒前
清秀苗条完成签到,获得积分10
2秒前
小红的忧伤完成签到,获得积分10
2秒前
清清发布了新的文献求助10
2秒前
邱继双完成签到,获得积分10
2秒前
3秒前
思源应助zhangyulong采纳,获得10
4秒前
爱科研的小潘完成签到,获得积分10
5秒前
稳重寻雪发布了新的文献求助10
5秒前
present完成签到,获得积分20
5秒前
Wangyingjie5发布了新的文献求助10
6秒前
我行我素完成签到 ,获得积分10
6秒前
lizhiqian2024发布了新的文献求助10
6秒前
香蕉觅云应助Light采纳,获得10
7秒前
黄老板发布了新的文献求助10
7秒前
科研通AI5应助科研通管家采纳,获得10
8秒前
JamesPei应助科研通管家采纳,获得10
9秒前
Akim应助科研通管家采纳,获得10
9秒前
我是老大应助科研通管家采纳,获得10
9秒前
CipherSage应助科研通管家采纳,获得30
9秒前
乐乐应助科研通管家采纳,获得10
9秒前
Orange应助科研通管家采纳,获得10
9秒前
9秒前
9秒前
9秒前
9秒前
ding应助科研通管家采纳,获得10
9秒前
如意板栗发布了新的文献求助10
10秒前
10秒前
11秒前
11秒前
NexusExplorer应助哈哈哈哈采纳,获得30
12秒前
黄老板完成签到,获得积分10
12秒前
13秒前
SciGPT应助lizhiqian2024采纳,获得10
15秒前
jin发布了新的文献求助10
15秒前
Wang发布了新的文献求助10
16秒前
与梦随行2011完成签到,获得积分10
17秒前
17秒前
高分求助中
Encyclopedia of Mathematical Physics 2nd edition 888
Introduction to Strong Mixing Conditions Volumes 1-3 500
Tip60 complex regulates eggshell formation and oviposition in the white-backed planthopper, providing effective targets for pest control 400
Optical and electric properties of monocrystalline synthetic diamond irradiated by neutrons 320
共融服務學習指南 300
Essentials of Pharmacoeconomics: Health Economics and Outcomes Research 3rd Edition. by Karen Rascati 300
Peking Blues // Liao San 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3802268
求助须知:如何正确求助?哪些是违规求助? 3348011
关于积分的说明 10335931
捐赠科研通 3063932
什么是DOI,文献DOI怎么找? 1682313
邀请新用户注册赠送积分活动 808016
科研通“疑难数据库(出版商)”最低求助积分说明 763997